Skip to main content
Journal cover image

Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging.

Publication ,  Journal Article
Debatin, JF; Nadel, SN; Gray, L; Friedman, HS; Trotter, P; Hockenberger, B; Oakes, WJ
Published in: Pediatr Radiol
1992

Twenty-two pediatric patients with known CNS neoplasms underwent magnetic resonance (MR) imaging before and after intravenous injection of 0.1 mmol/kg gadoteridol injection as part of a Phase IIIB open label multicenter clinical trial. Intravenous administration of this neutral, nonionic contrast agent was found to be safe in children. No clinically relevant changes in vital signs or laboratory values (including complete blood count, blood chemistry, serum electrolytes, thyroid and metabolic panel and clotting function) were attributed to the administration of gadoteridol injection. There were no systemic complaints. The imaging characteristics of gadoteridol in pediatric CNS disease appeared similar to those of gadopentetate dimeglumine. Contrast enhancement was present in 17 of 22 patients (77%). The administration of gadoteridol injection provided additional clinically relevant information including improved visualization and delineation of the primary lesion, detection of additional lesions, determination of tumor recurrence and narrowing the list of differential considerations in all 17 enhancing studies as well as in 2 of 5 studies without signal intensity enhancement. The very low toxicity, inherent to this nonionic low osmolal paramagnetic contrast formulation may allow administration of increased doses at increased infusion rates for an increased number of indications with improved sensitivity.

Duke Scholars

Published In

Pediatr Radiol

DOI

ISSN

0301-0449

Publication Date

1992

Volume

22

Issue

2

Start / End Page

93 / 98

Location

Germany

Related Subject Headings

  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Male
  • Magnetic Resonance Imaging
  • Injections, Intravenous
  • Infant
  • Humans
  • Heterocyclic Compounds
  • Gadolinium
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Debatin, J. F., Nadel, S. N., Gray, L., Friedman, H. S., Trotter, P., Hockenberger, B., & Oakes, W. J. (1992). Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging. Pediatr Radiol, 22(2), 93–98. https://doi.org/10.1007/BF02011303
Debatin, J. F., S. N. Nadel, L. Gray, H. S. Friedman, P. Trotter, B. Hockenberger, and W. J. Oakes. “Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging.Pediatr Radiol 22, no. 2 (1992): 93–98. https://doi.org/10.1007/BF02011303.
Debatin JF, Nadel SN, Gray L, Friedman HS, Trotter P, Hockenberger B, et al. Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging. Pediatr Radiol. 1992;22(2):93–8.
Debatin, J. F., et al. “Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging.Pediatr Radiol, vol. 22, no. 2, 1992, pp. 93–98. Pubmed, doi:10.1007/BF02011303.
Debatin JF, Nadel SN, Gray L, Friedman HS, Trotter P, Hockenberger B, Oakes WJ. Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging. Pediatr Radiol. 1992;22(2):93–98.
Journal cover image

Published In

Pediatr Radiol

DOI

ISSN

0301-0449

Publication Date

1992

Volume

22

Issue

2

Start / End Page

93 / 98

Location

Germany

Related Subject Headings

  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Male
  • Magnetic Resonance Imaging
  • Injections, Intravenous
  • Infant
  • Humans
  • Heterocyclic Compounds
  • Gadolinium
  • Female